Reach more patients
with more RNA medicines.

We have identified hundreds of novel receptor targets and use these discoveries to advance programs into the clinic. Our preclinical pipeline of receptor-targeted RNA medicines includes two lead candidates targeting lung and CNS tissue that are scheduled for IND-enabling studies in 2025.